Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: AzurRx BioPharma Inc. AZRX

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Issues Letter to Shareholders

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Biotech Showcase Digital 2021 Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the upcoming Biotech Showcase Digital 2021 conference. The multiday event is scheduled for Jan. 11–15, 2021. As part of the company’s planned participation, … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in H.C. Wainwright BioConnect Virtual Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in LifeSci Partners Corporate Access Event

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the 10th annual LifeSci Partners Corporate Access Event. As part of the company’s participation, AzurRx president and CEO James Sapirstein will present a … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Worldwide License Agreement with First Wave Bio, $8M Offerings

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, today announced its entry into an exclusive worldwide licensing agreement with First Wave Bio Inc. for the use of its patented and proprietary … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment